Skip to content
10-K

Annual Report

Damora Therapeutics, Inc. DMRA

0000950170-25-041981

← back to feed
Filed
Mar 19, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 14, 2025 1.32M sh
Shares Diluted restated FY 2024 · Dec 31, 2023 1.06M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$36.91M
Cash And Equivalents FY 2024 · Dec 31, 2023 $21.47M
Current Liabilities FY 2024 · Dec 31, 2023 $5.83M
Total Liabilities FY 2024 · Dec 31, 2023 $5.9M
Current Assets FY 2024 · Dec 31, 2023 $36.77M
Total Assets FY 2024 · Dec 31, 2023 $38.23M
Eps Diluted restated FY 2024 · Dec 31, 2023 −$36.08
Eps Basic restated FY 2024 · Dec 31, 2023 −$36.08
Sga Expense FY 2024 · Dec 31, 2023 $12.69M
Rd Expense FY 2024 · Dec 31, 2023 $23.77M
Net Income FY 2024 · Dec 31, 2023 −$38.35M
Operating Income FY 2024 · Dec 31, 2023 −$39.91M
Stockholders Equity FY 2024 · Dec 31, 2022 $61.75M